Zivo Bioscience Inc (ZIVO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Zivo Bioscience Inc (ZIVO) has a cash flow conversion efficiency ratio of 0.297x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.11 Million) by net assets ($-3.75 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Zivo Bioscience Inc balance sheet quality to measure how much of total assets are equity-financed.
Zivo Bioscience Inc - Cash Flow Conversion Efficiency Trend (2003–2025)
This chart illustrates how Zivo Bioscience Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Zivo Bioscience Inc earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Zivo Bioscience Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Zivo Bioscience Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Riley Gold Corp
V:RLYG
|
-0.026x |
|
Alton Sports Co.Ltd
KQ:123750
|
-0.165x |
|
Zamet Industry SA
WAR:ZMT
|
0.073x |
|
Kumpulan H & L High-Tech Bhd
KLSE:7033
|
0.035x |
|
Connection Technology Systems
TWO:3672
|
-0.009x |
|
Spackman Equit
V:SQG
|
0.040x |
|
Atalaya Mining Ltd
LSE:ATYM
|
0.039x |
|
Edesa Holding SA
BA:EDSH
|
0.067x |
Annual Cash Flow Conversion Efficiency for Zivo Bioscience Inc (2003–2025)
The table below shows the annual cash flow conversion efficiency of Zivo Bioscience Inc from 2003 to 2025. For the full company profile with market capitalisation and key ratios, see Zivo Bioscience Inc (ZIVO) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-3.75 Million | $-3.29 Million | 0.877x | -89.53% |
| 2024-12-31 | $-514.90K | $-4.31 Million | 8.377x | +218.61% |
| 2023-12-31 | $-2.21 Million | $-5.80 Million | 2.629x | -99.61% |
| 2022-12-31 | $-10.62K | $-7.10 Million | 668.670x | +59486.24% |
| 2021-12-31 | $6.04 Million | $-6.80 Million | -1.126x | -592.01% |
| 2020-12-31 | $-11.31 Million | $-2.59 Million | 0.229x | -48.53% |
| 2019-12-31 | $-8.34 Million | $-3.71 Million | 0.445x | +97.87% |
| 2018-12-31 | $-22.28 Million | $-5.01 Million | 0.225x | -13.66% |
| 2017-12-31 | $-16.30 Million | $-4.24 Million | 0.260x | +39.36% |
| 2016-12-31 | $-13.62 Million | $-2.54 Million | 0.187x | -22.79% |
| 2015-12-31 | $-9.50 Million | $-2.30 Million | 0.242x | -43.70% |
| 2014-12-31 | $-6.37 Million | $-2.74 Million | 0.430x | +38.01% |
| 2013-12-31 | $-9.59 Million | $-2.99 Million | 0.311x | -30.56% |
| 2012-12-31 | $-3.96 Million | $-1.77 Million | 0.448x | -29.64% |
| 2011-12-31 | $-2.03 Million | $-1.29 Million | 0.637x | -57.89% |
| 2010-12-31 | $-951.68K | $-1.44 Million | 1.513x | +397.95% |
| 2009-12-31 | $-3.79 Million | $-1.15 Million | 0.304x | -83.13% |
| 2008-12-31 | $-519.60K | $-935.82K | 1.801x | -3.29% |
| 2007-12-31 | $-755.37K | $-1.41 Million | 1.862x | -25.79% |
| 2006-12-31 | $-832.54K | $-2.09 Million | 2.510x | -10.22% |
| 2005-12-31 | $-590.09K | $-1.65 Million | 2.795x | +140.67% |
| 2004-12-31 | $-1.10 Million | $-1.28 Million | 1.161x | +139.94% |
| 2003-12-31 | $-35.94K | $-17.39K | 0.484x | -- |
About Zivo Bioscience Inc
ZIVO Bioscience, Inc., together with its subsidiaries, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically act… Read more